No-Flush Niacin 500 mg

No-Flush Niacin 500 mg

Source Naturals4.7 (1,597 ratings)
Format:Tablet Quantity: 60 Tablet(s) · 60 servings
Goals
$9.95 $0.16 per serving

Product analysis

74 out of 100

No-Flush Niacin 500 mg offers a clearly labeled inositol hexanicotinate supplement, but a heart-health benefit from this form remains unestablished.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality70

The niacin form is clearly identified, which makes the type supplied easy to check. The quality of the inositol contribution cannot be judged with the same confidence.

Ingredient Transparency100

The declared niacin and inositol amounts and forms are stated. Both refer to inositol hexanicotinate, so they should not be read as proof of two separate health effects.

Value For Money100

The declared niacin form has favorable value. The finding concerns the supplement provided per serving, while suitability still depends on the purpose of taking it.

Customer Satisfaction84

Customer feedback is very positive across more than a thousand ratings. That is useful for judging satisfaction but does not establish cardiovascular benefits.

Product Focus0

The supplement is narrowly centered on inositol hexanicotinate. A cardiovascular role for this form is not established, and evidence for a different niacin form cannot simply be applied to it.

Format
Tablet
Container
60 Tablet(s)
Per serving
$0.16
Customer rating
4.7 · 1,597 ratings
Report analysis

Goals

Cardiovascular Support
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Niacin · 500 mg

No-Flush Niacin 500 mg declares 500 mg inositol hexanicotinate per serving, but the supplied cardiovascular evidence doesn't give this form a role as studied nicotinic-acid support. That leaves no established amount or pathway for this goal; this missing match doesn't prove the ingredient is clinically ineffective.

How this product is rated for Cardiovascular Support

Ingredient fit28

The sole active declaration is 500 mg inositol hexanicotinate; inositol is also listed, but a studied nicotinic-acid amount isn't established.
Goal fit
The label names an alternative niacin preparation, with no cardiovascular role established for this form.
Dose adequacy
The 500 mg is the mass of inositol hexanicotinate, not a measured active nicotinic-acid amount.

Pathways0

The supplied details don't connect the listed preparation to a cardiovascular marker pathway.
Depth
No cardiovascular pathway is established for this listed niacin form.
Breadth
No second cardiovascular pathway is supported in the supplied details.

Evidence0

The supplied material doesn't establish this preparation's cardiovascular effect; that doesn't prove clinical ineffectiveness.
Evidence strength
No active ingredient reaches a studied cardiovascular exposure in the listed preparation.
Studied preparation
Inositol hexanicotinate isn't identified as the nicotinic-acid preparation used in supplied cardiovascular trials.

Formulation logic35

No direct ingredient matches the cardiovascular preparation and dose context; no conflict is listed.
Partner coverage
No eligible active preparation is available to assess for a needed partner.
Conflicts
No listed stimulant or high-sodium conflict is present.
Effective doses
The 500 mg declaration is for the ester; an active niacin amount in a cardiovascular form isn't established.
Study evidence
Niacin Supportive 136 studies
Heart Health
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per servingScore
Niacin (Inositol Hexanicotinate)
500 mg 76
Inositol (Inositol Hexanicotinate)
143 mg
Gluten Free Adults 18–50 Dairy Free Sugar Free Vegetarian
Report overview
C Active Ingredient Quality & BioavailabilityB Dose, Safety & Label TransparencyA+ Value
Each serving provides 500 mg of niacin from inositol hexanicotinate. A no-flush claim is recorded, and the whole product costs about $0.17 per serving.
How this ingredient is rated

Active Ingredient Quality & Bioavailability64

Inositol hexanicotinate is the recorded form, and the product is marketed for heart support.
Niacin Form & Goal Alignment
Inositol hexanicotinate is the recorded form in a product marketed for heart support.
Precursor Source Quality
Inositol hexanicotinate is the recorded source; no advanced precursor is identified in the saved facts.

Dose, Safety & Label Transparency75

The serving provides 500 mg of niacin in the identified form. A no-flush claim is recorded.
Clarity of Chemical Form
The recorded niacin source is inositol hexanicotinate.
Form-Specific Dosage Efficacy
A serving provides 500 mg of niacin.
Flush Risk & Safety Labeling
The product carries a no-flush claim for the inositol hexanicotinate source.

Value100

The whole product costs about $0.17 per serving.
Price Per Effective Serving
The whole product costs about $0.17 per serving.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  2. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  3. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  5. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  6. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  7. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  8. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  9. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  10. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin